Last reviewed · How we verify
HB0043
At a glance
| Generic name | HB0043 |
|---|---|
| Also known as | recombinant humanized IgG1 bispecific antibody targeting both IL-17A and IL-36R. |
| Sponsor | Shanghai Huaota Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. (PHASE1, PHASE2)
- Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. (PHASE1, PHASE2)
- A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB0043 CI brief — competitive landscape report
- HB0043 updates RSS · CI watch RSS
- Shanghai Huaota Biopharmaceutical Co., Ltd. portfolio CI